Covered recipient · General Payments record
CAROLINE ZHU
General Payments · PY2023–2025
$5,348.66
- Reported across 49 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,608.88 | 15 |
| Education | $72.00 | 1 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GENZYME CORPORATION | $708.22 | 7 |
| Janssen Biotech, Inc. | $239.94 | 3 |
| Amgen Inc. | $232.38 | 2 |
| Galderma Laboratories, L.P. | $169.78 | 1 |
| Biofrontera Inc. | $128.86 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $103.38 | 1 |
| Lilly USA, LLC | $98.32 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (16)
Sorted by paying entity, then date · as published by CMS
Program year 2025 20232024
Record-level detail is published for PY2025; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $120.45 | 02/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228676015 | CMS |
| Amgen Inc. | $111.93 | 03/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228676017 | CMS |
| Biofrontera Inc. | $128.86 | 03/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1208908776 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $103.38 | 05/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1222745265 | CMS |
| Galderma Laboratories, L.P. | $169.78 | 10/23/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234720963 | CMS |
| GENZYME CORPORATION | $109.07 | 02/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233679724 | CMS |
| GENZYME CORPORATION | $37.64 | 03/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233679730 | CMS |
| GENZYME CORPORATION | $120.61 | 05/06/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233679742 | CMS |
| GENZYME CORPORATION | $133.96 | 06/23/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233679744 | CMS |
| GENZYME CORPORATION | $149.52 | 07/28/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233679748 | CMS |
| GENZYME CORPORATION | $111.73 | 08/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233679756 | CMS |
| GENZYME CORPORATION | $45.69 | 09/30/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233679772 | CMS |
| Janssen Biotech, Inc. | $72.00 | 10/08/2025 | Education | Undisputed | 06/30/2026 | 1174988591 | CMS |
| Janssen Biotech, Inc. | $145.64 | 10/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1174993363 | CMS |
| Janssen Biotech, Inc. | $22.30 | 12/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1174985651 | CMS |
| Lilly USA, LLC | $98.32 | 05/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186545559 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.